Imago Biosciences Inc

Imago Biosciences — Technical Presentation (December 2021)

16 slides from Imago Biosciences's technical presentation, Dec 13, 2021

  1. Slide 1: Disclosures

    Disclosures Palandri, F. – Nothing to disclose Bomedemstat is an investigational drug has not yet been approved by the US Food and Drug Administration and is only available through clinical trial participation Abstract #386: Bomedemstat in ET Exhibit 99.4

  2. Slide 2: Phase 2 Study of the LSD1 Inhibitor IMG-7289 (Bomedemstat) for Essential Thrombocythemia

    Phase 2 Study of the LSD1 Inhibitor IMG-7289 (Bomedemstat) for the Treatment of Essential Thrombocythemia (ET) Francesca Palandri, MD, PhD1*, David M Ross, MBBS, PhD, FRACP, FRCPA4*, Tara Cochrane, MBBS, FRCPA, FRACP5, Steven W Lane, MD, PhD6, Stephen R Larsen, MBBS PhD FRACP FRCPA7, Aaron T. Gerds,

  3. Slide 3: LSD1 is a key regulator of hematopoietic differentiation

    LSD1 is a key regulator of hematopoietic differentiation Abstract #386: Bomedemstat in ET LSD1 (Lysine-specific demethylase 1) demethylates H3K4 and other chromatin-associated proteins, e.g., p53 Loss of LSD1 activity is associated with loss of self-renewal in malignant HSCs1 LSD1 is required for th

  4. Slide 4: Introduction to Bomedemstat

    Introduction to Bomedemstat Bomedemstat is an irreversible inhibitor of LSD1 Discovered and developed by Imago PK and dose-response data support once-daily dosing No apparent penetration across the blood-brain barrier Bomedemstat has been evaluated in 170+ patients with advanced myeloid malignancies

  5. Slide 5: Study Design

    Study Design Abstract #386: Bomedemstat in ET Safety and tolerability Platelet count reduction (≤400 x 109/L) in the absence of thromboembolic events Primary Endpoints Key Eligibility Criteria Secondary Endpoints Symptom reduction (MPN-SAF TSS) Durability of platelet and WBC count reduction Changes

  6. Slide 6: Bomedemstat Treatment Plan

    Bomedemstat Treatment Plan IMG-7289 (bomedemstat) PO once daily (QD) Each patient dose-titrated to platelet count per dosing rules Starting dose is 0.6 mg/kg QD Up-titrations may occur every 4 weeks to target platelet range of 200-400 x 109/L Abstract #386: Bomedemstat in ET Platelet Count (x 109/L)

  7. Slide 7: Enrollment and Treatment Status

    Enrollment and Treatment Status Abstract #386: Bomedemstat in ET Data cut-off date: 01 Nov 2021 Place Video Here Days on Study

  8. Slide 8: Baseline Characteristics

    Baseline Characteristics Abstract #386: Bomedemstat in ET Characteristic N = 36 Median age (range) 68 (42 – 85) Male 15 (42%) Mean blood counts (range)# WBC Hemoglobin Platelet Count #1 value missing 9.4 x 109/L (4.4 – 30.6) 13.1 x g/dL (9.4* – 16.5) 863 x 109/L (457 – 2220) Mutations (%) JAK2 CALR

  9. Slide 9: Safety and Tolerability

    Safety and Tolerability Bomedemstat is generally well-tolerated with few Grade 3/4 AEs (3.6%; 12/335) Most common AE was dysgeusia – all events were Grade 1/2 with 2/18 leading to treatment discontinuation Eight SAEs, two of which were related and both led to dose interruption (thrombocytopenia and

  10. Slide 10: Primary Objective: Reduction in Platelet Count

    Primary Objective: Reduction in Platelet Count Abstract #386: Bomedemstat in ET In the 29 patients treated for >6 weeks: 100% patients experienced a reduction in platelets 93% of patients achieved a platelet count of ≤400 x 109/L Response Rate*: 90% (26/29) Mean Platelet Count (±95% CI) N=33 Platele

  11. Slide 11: Primary Objective: Reduction in Platelet Count

    Primary Objective: Reduction in Platelet Count In the 27 patients treated for at least 12 weeks: Mean reduction of 496 x 109/L at Week 12 (N=27) Durability of response: to date 52% of patients achieved 12 consecutive weeks ≤400 x 109/L Abstract #386: Bomedemstat in ET *Patient off drug for up to 6 w

  12. Slide 12: Platelet Count Response Across Mutation Status

    Platelet Count Response Across Mutation Status Mutation No. of Patients* Mean Baseline Platelet Count (x109/L) Platelet Count Response (%) All Pts 30 838 93% CALR 13 993 100% JAK2V617F 13 765 83% Triple Negative 2 524 100% *Patients with mutation status and platelet counts available Patients with CA

  13. Slide 13: Lowers WBC and Maintains Hemoglobin Levels

    Lowers WBC and Maintains Hemoglobin Levels Abstract #386: Bomedemstat in ET Mean WBC (±95% CI) N=33 Mean Hemoglobin (±95% CI) N=32 Hemoglobin g/dL WBC Count x 109/L Weeks of treatment Weeks of treatment Data cut-off date: 01 Nov 2021 Place Video Here

  14. Slide 14: Reduction in Total Symptom Score

    Reduction in Total Symptom Score Abstract #386: Bomedemstat in ET TSS % Change at 24 weeks (Patients with >0 at Day 1, N=17) N at Day 1 with Score >0 = 31 NB 1 excluded (012-202) 71% had a decrease in TSS 53% had a decrease of >50% 47% had a decrease of ≥10 points Data cut-off date: 01 Nov 2021 Plac

  15. Slide 15: Conclusions

    Conclusions Bomedemstat (IMG-7289) is generally well tolerated in ET patients Majority of AEs were low-grade Bomedemstat as monotherapy demonstrates significant clinical activity: Normalization of platelet and WBC counts while maintaining hemoglobin Symptomatic improvement for some patients with sig

  16. Slide 16: Thank you to Investigators and Study Participants!

    Thank you to Investigators and Study Participants! Abstract #386: Bomedemstat in ET Investigators - Europe Francesca Palandri & Nicola Vianelli – Bologna, Italy Monia Marchetti, Alessandria, Italy Alessandro Vannucchi – Firenze, Italy Francesco Passamonti – Varese, Italy Joachim Göthert – Essen, Ger

Imago BioSciences — Technical Presentation (December 2021) on 6ix